Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer

Withdrawn before enrolling · Not applicable

Conditions studied: Metastatic Prostate Cancer

In brief

The investigators aim to test the safety and feasibility of prostate gland stereotactic body radiotherapy (SBRT) plus best systemic therapy in newly diagnosed metastatic prostate cancer.

Key facts

Study ID

NCT02206724

Run by

Sharp HealthCare

People needed

0

Starts

2014-07-16

Expected to finish

2018-04-17

Last updated by the study team

2018-04-20

Who can join

Age: 18 and older, up to 75. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-confirmed, adenocarcinoma of the prostate
• Clinical Stage T1b - T4, NX-0-1, M1
• Any Gleason score
• PSA<1000
• ECOG Performance Status 0-2
• No prior prostate radiation or other definitive therapy

You may not qualify if…

• Prior prostatectomy or cryotherapy of the prostate
• Prior radiotherapy to the prostate or lower pelvis
• Implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion
• Chemotherapy for a malignancy in the last 5 years
• History of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years

Where it is running

• Sharp Healthcare — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.